The Journal of Immunology, Vol 136, Issue 5 1629-1634, Copyright © 1986 by American Association of Immunologists

ARTICLES

Establishment of an interleukin 2-dependent T cell line derived from a patient with severe aplastic anemia, which inhibits in vitro hematopoiesis

F Herrmann, JD Griffin, SG Meuer and KH Meyer zum Buschenfelde

Circulating mononuclear cells from a patient developing severe aplastic anemia during the course of non-A, non-B hepatitis were found to be virtually entirely composed of in vivo activated suppressor T cells (Ia+T8+). These cells were used to establish a new permanent cell line, termed SMAA, by using phytohemagglutinin, Ebstein-Barr virus- transformed irradiated B cells, allogeneic irradiated peripheral blood mononuclear cells, and recombinant interleukin 2 to investigate the relationship of aplastic anemia-derived circulating T cells to bone marrow failure. SMAA cells, now in continuous culture for more than 9 mo, were shown to inhibit proliferation of purified myeloid progenitors and their differentiation into early and late appearing neutrophil and eosinophil colonies by 90%, whereas monocyte colonies were much less affected. Similarly, growth of erythroid colonies and bursts was almost completely inhibited, as was anti-mu-induced B cell proliferation and lectin-induced T cell proliferation. This inhibition of hematopoiesis was mediated by the release of a soluble factor that was sensitive to acid (pH 2), heat (56 degrees C), and trypsin. Monoclonal and polyclonal antibodies to interferon-gamma could abrogate the inhibitory effects of SMAA supernatant, but more than 10(4) neutralizing U/ml had to be added. The effects of SMAA could be duplicated by adding 10(4) U/ml of purified recombinant interferon-gamma to colony and proliferation assays. The concentration of interferon-gamma in SMAA supernatant was estimated to be greater than 3 X 10(3) National Institutes of Health reference U/ml by immunoradiometric assay. These results demonstrate that some patients with aplastic anemia have circulating T cells that are capable of prolonged in vitro secretion of interferon-gamma causing severe inhibition of in vitro hematopoiesis, and these cells can be expanded into permanent lines for studies on their regulatory properties.

This article has been cited by other articles:

				H. Takamatsu, X. Feng, T. Chuhjo, X. Lu, C. Sugimori, K. Okawa, M. Yamamoto, S. Iseki, and S. Nakao Specific antibodies to moesin, a membrane-cytoskeleton linker protein, are frequently detected in patients with acquired aplastic anemia Blood, March 15, 2007; 109(6): 2514 - 2520. [Abstract] [Full Text] [PDF]

				X. Feng, T. Chuhjo, C. Sugimori, T. Kotani, X. Lu, A. Takami, H. Takamatsu, H. Yamazaki, and S. Nakao Diazepam-binding inhibitor-related protein 1: a candidate autoantigen in acquired aplastic anemia patients harboring a minor population of paroxysmal nocturnal hemoglobinuria-type cells Blood, October 15, 2004; 104(8): 2425 - 2431. [Abstract] [Full Text] [PDF]

				N. Hirano, M. O. Butler, M. S. von Bergwelt-Baildon, B. Maecker, J. L. Schultze, K. C. O'Connor, P. H. Schur, S. Kojima, E. C. Guinan, and L. M. Nadler Autoantibodies frequently detected in patients with aplastic anemia Blood, December 15, 2003; 102(13): 4567 - 4575. [Abstract] [Full Text] [PDF]

				S. Nakao, A. Takami, H. Takamatsu, W. Zeng, N. Sugimori, H. Yamazaki, Y. Miura, M. Ueda, S. Shiobara, T. Yoshioka, et al. Isolation of a T-Cell Clone Showing HLA-DRB1*0405-Restricted Cytotoxicity for Hematopoietic Cells in a Patient With Aplastic Anemia Blood, May 15, 1997; 89(10): 3691 - 3699. [Abstract] [Full Text] [PDF]

				K. Shannon, W. Koehne, M. B. Heyman, and M. A. Koerper Relapsing Post-hepatitis Aplastic Anemia: Immunosuppressive Therapy Clinical Pediatrics, January 1, 1990; 29(1): 25 - 29. [Abstract] [PDF]